We rank companies based on fund manager, research analyst and news sentiment
ALZN stock icon

Alzamend Neuro, Inc. Common Stock


About: Alzamend Neuro Inc is an early clinical-stage biopharmaceutical company. It is focused on developing novel products for the treatment of neurodegenerative diseases and psychiatric disorders, including Alzheimer's. Its mission is to develop and market safe and effective treatments. The company's pipeline consists of two novel therapeutic drug candidates, AL001 - a patented ionic cocrystal technology delivering lithium via a therapeutic combination of lithium, proline and salicylate, and AL002 - a patented method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine that seeks to restore the ability of a patient's immunological system to combat Alzheimer's.

Employees: 7

Funds holding %
of 6,474 funds
Analysts bullish %
News positive %

Fund manager confidence

Based on 2023 Q4 SEC filings by fund managers ($100M+ AUM)

1.2% less ownership

Funds ownership: 6.46% [Q3] → 5.26% (-1.2%) [Q4]

38% less funds holding

Funds holding: 26 [Q3] → 16 (-10) [Q4]

71% less first-time investments, than exits

New positions opened: 4 | Existing positions closed: 14

77% less capital invested

Capital invested by funds: $1.48M [Q3] → $335K (-$1.15M) [Q4]

100% less repeat investments, than reductions

Existing positions increased: 0 | Existing positions reduced: 12

Research analyst outlook

We haven’t received any recent analyst ratings for ALZN.

Financial journalist opinion